Jazz Buys Rare Epilepsy Drug Company for Up to $1.32 Billion
Jazz Pharmaceuticals acquires Actio Biosciences for up to $1.32 billion, adding experimental drug ABS-1230 for rare KCNT1 epilepsy with no approved treatments.
/ 492 items
#XY Event-Driven Stocks↓
Silence Therapeutics’ Divesiran Delivers Strong Phase 2 Results in Rare Blood Cancer, Setting Up Challenge to Takeda
Silence Therapeutics reports 88% response rate for divesiran in polycythemia vera Phase 2 trial. Quarterly dosing could challenge Takeda’s rusfertide.
Tenax’s TNX-103 Misses Primary Endpoint in Late-Stage Heart Failure Trial
Tenax’s heart drug trial missed its main goal, but showed promise in sicker patients, sending shares down more than 85%.
Sionna Therapeutics Stock Plunges After Cystic Fibrosis Trial Failure; Vertex Rises on Reduced Competition
Will not advance SION-719 add-on; Vertex sees relief from rivalry.
AbCellera’s Single-Dose Menopause Treatment Delivers Big Reduction in Hot Flashes
AbCellera shares jumped after its menopause drug reduced hot flashes by 83% in a Phase 2 trial, with no serious side effects reported.
Varex Imaging Shares Surge 49% After Teledyne Agrees to $1.1 Billion Acquisition
Teledyne will acquire Varex Imaging for $18.90 per share.